MGC Pharma

NOVEMBER 1, 2017

This is a big moment for me and the MGC Pharmaceuticals team. Needless to say, I have been waiting a long time to write the following sentence: MGC Pharmaceuticals has just released their first product to the market. CannEpil™ is CBD-based medication that is used as a treatment for people with refractory epilepsy.

Epilepsy 100

Epilepsy Pharmaceutical Medicine CBD 100

Veriheal

FEBRUARY 21, 2023

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies. How Do MMJ Restrictions Affect Patients and Doctors?

Access 98

Access Patients Chronic Pain Conditions 98

MGC Pharma

APRIL 4, 2018

A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals. CBD-based treatment for people with Refractory Epilepsy?—?is Refractory Epilepsy is epilepsy that involves frequent and severe seizures that are difficult to treat. CannEpil™?—?CBD-based

Epilepsy 100

Epilepsy Pharmaceutical Research and Development CBD 100

CannaTech

JANUARY 16, 2019

Thanks to the recent emergence of regulated medical cannabis markets, the success of this versatile plant can be followed from farm to pharma and prescriber to patient, however, the origins of cannabis as medicine cannot be as simply traced as the plant is today from seed to sale. Of course, patients need product and product costs money.

Access 89

Access Patients Pharmaceutical Education 89

Cannabis Law Report

DECEMBER 23, 2021

DUBLIN–(BUSINESS WIRE)– “The Pharmaceutical Cannabis Report: 2nd Edition” report has been added to ResearchAndMarkets.com’s offering. In both Europe and the United States, the sales of unapproved cannabis products such as smokable flower and full spectrum oils dwarf those of approved pharmaceuticals.

Pharmaceutical 74

Pharmaceutical Clinical Trials Research and Development Cannabinoids 74

Cannabis Law Report

JULY 12, 2019

Side effects were very prevalent in 79% of all patients taking a refined CBD product, some of which were severe like thrombocytopenia and transaminase elevations in the liver. Review: During an open-label trial of pure CBD with Lennox-Gastaut and Dravet patients, 79% of all patients reported side effects.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. RADNOR, Pa.–(BUSINESS

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Cannabis Law Report

JANUARY 15, 2019

British firm GW Pharmaceuticals is licking its wounds after US judges tossed out its attempt to patent multiple cannabinoids for epilepsy treatment following an eight-year battle. The patent, which has been embroiled in dispute since 2010, is for “the use of one or more cannabinoids in the treatment of epilepsy”.

Epilepsy 71

Epilepsy Cannabinoids Treatment Research and Development 71

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? What do experts say? PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

WeedAdvisor

SEPTEMBER 24, 2019

GW Pharmaceuticals created the medication after studies showed surprising success treating severe childhood epilepsy, specifically Lennox-Gastaut Syndrome and Dravet Syndrome. study, the 26,000 Dravet and 130,000 LGS patients in Europe have a new alternative that could bring hope to a seemingly hopeless situation. In the U.S.,

Epilepsy 49

Epilepsy CBD Pharmaceutical Access 49

MMJ Recs

NOVEMBER 20, 2023

Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition. These compounds may help reduce symptoms and improve the quality of life for patients. The outcomes of these studies have had a profound impact on patient care.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Cannabis Law Report

AUGUST 24, 2021

BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. Thus, there is a great need to develop new and effective therapeutics for treating patients. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 75

Pharmaceutical Clinical Trials Chronic Pain CBD 75

MassRoots

JANUARY 10, 2019

Lawmakers have been listening to constituents suffering from debilitating diseases, like epilepsy and cancer, who say they would like to have the option to explore how medical cannabis may ease their symptoms. Cassie Everett, a woman from Louisville who suffers from epilepsy contacted Rep. Why Medical Marijuana? Nemes said.

Legalization 111

Legalization Marijuana Epilepsy Legislation 111

MGC Pharma

DECEMBER 12, 2017

A word from Elad Segev, Manager of Breeding and Cultivation at MGC Pharmaceuticals. Firstly, recent research has suggested that THC can help relieve pain in many patients. This effect can be put to very good use to help patients suffering from cancer or HIV/AIDS eliminate any uncomfortable nausea that their treatments provoke.

Epilepsy 100

Epilepsy Pharmaceutical Cannabinoids THC 100

CannaTech

SEPTEMBER 23, 2019

The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

MGC Pharma

FEBRUARY 15, 2018

A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals Right now in Australia, access to Cannabis-based treatments is heavily restricted. Physicians who want to prescribe Medicinal Cannabis are required to jump through countless regulatory hoops, as are patients seeking treatment.

Access 100

Access Medicine Chronic Pain Research and Development 100

Veriheal

SEPTEMBER 16, 2020

Epidiolex is the sole cannabis-derived pharmaceutical that has been approved by the FDA – although it is worth noting that the organization has also approved three synthetic cannabis-related products. Though these tumors are noncancerous in nature, their presence can cause health problems, including epilepsy. What is Epidiolex?

Access 98

Access Epilepsy Treatment Conditions 98

Cannabis Law Report

DECEMBER 3, 2021

.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Chief Executive Officer of Marinus Pharmaceuticals. “We Relative changes in alpha/delta ratio and suppression ratio correlated with measured serum ganaxolone levels.

Epilepsy 40

Epilepsy Pharmaceutical Data Clinical Trials 40

The Cannigma

JUNE 1, 2021

Under the plan, some 3,000 patients in France will be treated with medical cannabis and monitored closely. Patients can take part if they have a medical condition which has not responded to pharmaceutical drugs. Patients can take part if they have a medical condition which has not responded to pharmaceutical drugs.

Law 112

Law Epilepsy Programs Patients 112

Peninsula Alternative Health

MAY 15, 2019

Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

Otherside Farms

JANUARY 24, 2019

Federal regulators have approved two clinical studies testing whether a marijuana-based epilepsy drug may help prevent seizures among epileptic children. Although both studies will enroll 25 patients initially, the U.S. Source: FDA Approves Marijuana-Based Epilepsy Drug For Use On Kids In Clinical Trials. In the upcoming U.S.

Clinical Trials 45

Clinical Trials Epilepsy Marijuana Pharmaceutical 45

CannaTech

APRIL 1, 2020

When I was at Pharmacy School at Sydney University, more than 20 years ago, we learned the pharmaceutical and clinical sciences ranging from the design, synthesis, formulation, dispensing and testing of drugs and the clinical and social aspects of pharmacy. And most especially in these times, cannabis is used effectively to treat anxiety.

Supply Chain 98

Supply Chain Chronic Pain Pharmaceutical Patients 98

Cannabis Law Report

JULY 30, 2019

Following an encouraging initial US launch, GW Pharmaceuticals’s cannabidiol oral solution is also set to achieve European approval later in 2019. The US approval of Zogenix’s Fintepla, a potential competitor for GW’s drug, has been delayed but still lo… The European Pharmaceutical Review reports.

Epilepsy 40

Epilepsy Pharmaceutical Medicine Treatment 40

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Montefiore Medical Center in New York and GW Pharmaceuticals are examining the effects of a cannabis compound when administered to children on the autism spectrum.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

Cannabis Law Report

SEPTEMBER 29, 2022

Australia’s drugs regulator issues 73 infringement notices over claims prescriptions could treat conditions such as cancer and epilepsy. The Therapeutic Goods Administration (TGA) issued 73 infringement notices totalling $972,360 between the medicinal cannabis companies MGC Pharmaceuticals Ltd, Cannatrek Ltd and Little Green Pharma Ltd.

Epilepsy 52

Epilepsy Conditions Media Medicine 52

CannaTech

MAY 14, 2020

When I studied pharmaceutical science at Sydney University 24 years ago we were not taught about the Endocannabinoid System (ECS). Together the two courses taught me everything I need to know in order to knowledgeably counsel my patients on the correct use of cannabis medicine. I am a pharmacist.

Patients 59

Patients Epilepsy Education THC 59

United Patients Group

APRIL 18, 2023

Because they often combine it with other drugs like cocaine or heroin or even legal ‘prescribed’ pharmaceuticals–and those are far more dangerous than cannabis itself! In fact, there are some patients who prefer not to smoke because of their health conditions or other reasons. Myth: Cannabis is a cure-all.

Research and Development 116

Research and Development Indica Treatment Conditions 116

MMJ Recs

NOVEMBER 17, 2023

This article explores the profound impact of MMJ on Maryland communities, shedding light on the medical marijuana benefits experienced by patients and the positive effects it has had on the state’s communities. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

MMJ Recs

MAY 15, 2022

This initial MMJ legislation only allowed patients suffering from intractable epilepsy to use cannabis oil. In 2020, the law changed to allow patients with any medical condition to receive a doctor’s recommendation to use and purchase medical marijuana products containing a maximum 10 milligrams of THC.

Patients 52

Patients Marijuana Pharmaceutical Dispensary 52

Cannabis Law Report

SEPTEMBER 28, 2021

DUBLIN–(BUSINESS WIRE)–The “Epilepsy – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This Epilepsy – Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.

Epilepsy 40

Epilepsy Clinical Trials Research and Development Pharmaceutical 40

Cannabis Law Report

JULY 26, 2021

OTCQB: SPRCY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced a number of updates regarding its Phase IIb clinical study in Tourette Syndrome using the proprietary cannabinoid-based treatment- SCI-110. About SciSparc (OTCQB: SPRCY): SciSparc Ltd.

Research and Development 105

Research and Development Supply Chain Pharmaceutical Treatment 105

CannaMD

JULY 14, 2020

Polypharmacy is a growing problem where patients are prescribed multiple different medications simultaneously in order to treat a given medical condition. It’s often mistakenly believed that taking multiple medications results in better management of a patient’s symptoms, but often that’s simply not the case. WHAT IS POLYPHARMACY?

Marijuana 105

Marijuana Conditions Patients Epilepsy 105

Cannabis Law Report

JANUARY 16, 2022

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) previously approved a prescription medicine derived from cannabis in 2014 to treat muscle spasms and spasticity from multiple sclerosis. Sativex was developed by GW Pharmaceuticals, a maker of cannabinoid therapeutics based in Ireland.

Pharmaceutical 98

Pharmaceutical Research and Development Epilepsy Medicine 98

Canna Law Blog

MARCH 12, 2019

9,066,920 – “Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy” (“the 920 Patent”). GW Pharma”) and Otsuka Pharmaceuticals Co., Epidiolex was approved to treat two rare forms of epilepsy: Dravet syndrome and Lennox-Gastaut syndrome. In this case, the subject patent was U.S.

Epilepsy 87

Epilepsy Pharmaceutical Cannabinoids CBD 87

Canna Care Docs

SEPTEMBER 18, 2020

Patients under the age of 18 must also have a parent or guardian registered as a caregiver on their behalf. Patients may purchase a 90 day supply of their medication. Patients may purchase medical cannabis in oil-based preparations such as lozenges, capsules, and vape pens. Can a Qualifying Patient Grow Cannabis in Virginia?

Pharmaceutical 98

Pharmaceutical Conditions Patients Oil 98

Medicinal Marijuana Association

JANUARY 19, 2019

Many experts believe that cannabis is a safe alternative to pharmaceuticals for relieving symptoms related to many illnesses. The politics associated with the so-called war on drugs in the country have forced the issue in the hands of the governments, rather than with patients and doctors, where the decision should ultimately lie.

Legalization 75

Legalization Pharmaceutical Chronic Pain Patients 75